Cipla eyeing fresh JV with China's Desano?
ET Now learns from sources that pharma major Cipla is looking to renew its ties with Shanghai-based Desano and is eyeing a joint venture with a 75:25 split. The JV, talks of which are likely at a binding stage, may cover both Active Pharmaceutical Ingredients (API) and formulations segments. Dipshikha Ghosh brings you more details.
Other Pharmaceuticals Videos
AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence
The brutal leadership lesson that shaped Dr. Reddy’s chief
We are discovery rich, but development poor
Budget 2026: India’s pharma leap, BioPharma SHAKTI gets ₹10K cr; 1,000 clinical trial sites planned
Corner Office Conversation: Nandini Piramal of Piramal Pharma & Arjun Juneja of Mankind Pharma
